Cara Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Tvardi Therapeutics reported its lead candidate TTI-101 failed to meet goals in a Phase 2 IPF trial, while advancing its HCC program and acknowledging substantial future capital needs.
Tvardi Therapeutics, formed from a reverse merger with Cara Therapeutics, filed an S-1/A for the resale of 2.08 million common shares by existing stockholders, as it advances its STAT3 inhibitor pipeline for fibrosis-driven diseases.
Tvardi Therapeutics, formerly Cara Therapeutics, has completed its reverse merger, establishing itself as a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies targeting STAT3 for fibrosis-driven diseases, including idiopathic pulmonary fibrosis and hepatocellular carcinoma.